<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36573005</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>03</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Three-Month Symptom Profiles Among Symptomatic Adults With Positive and Negative Severe Acute Respiratory Syndrome Coronavirus 2 Tests: A Prospective Cohort Study From the INSPIRE Group.</ArticleTitle><Pagination><StartPage>1559</StartPage><EndPage>1566</EndPage><MedlinePgn>1559-1566</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciac966</ELocationID><Abstract><AbstractText Label="BACKGROUND">Long-term symptoms following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are a major concern, yet their prevalence is poorly understood.</AbstractText><AbstractText Label="METHODS">We conducted a prospective cohort study comparing adults with SARS-CoV-2 infection (coronavirus disease-positive [COVID+]) with adults who tested negative (COVID-), enrolled within 28 days of a Food and Drug Administration (FDA)-approved SARS-CoV-2 test result for active symptoms. Sociodemographic characteristics, symptoms of SARS-CoV-2 infection (assessed with the Centers for Disease Control and Prevention [CDC] Person Under Investigation Symptom List), and symptoms of post-infectious syndromes (ie, fatigue, sleep quality, muscle/joint pains, unrefreshing sleep, and dizziness/fainting, assessed with CDC Short Symptom Screener for myalgic encephalomyelitis/chronic fatigue syndrome) were assessed at baseline and 3 months via electronic surveys sent via text or email.</AbstractText><AbstractText Label="RESULTS">Among the first 1000 participants, 722 were COVID+ and 278 were COVID-. Mean age was 41.5 (SD 15.2); 66.3% were female, 13.4% were Black, and 15.3% were Hispanic. At baseline, SARS-CoV-2 symptoms were more common in the COVID+ group than the COVID- group. At 3 months, SARS-CoV-2 symptoms declined in both groups, although were more prevalent in the COVID+ group: upper respiratory symptoms/head/eyes/ears/nose/throat (HEENT; 37.3% vs 20.9%), constitutional (28.8% vs 19.4%), musculoskeletal (19.5% vs 14.7%), pulmonary (17.6% vs 12.2%), cardiovascular (10.0% vs 7.2%), and gastrointestinal (8.7% vs 8.3%); only 50.2% and 73.3% reported no symptoms at all. Symptoms of post-infectious syndromes were similarly prevalent among the COVID+ and COVID- groups at 3 months.</AbstractText><AbstractText Label="CONCLUSIONS">Approximately half of COVID+ participants, as compared with one-quarter of COVID- participants, had at least 1 SARS-CoV-2 symptom at 3 months, highlighting the need for future work to distinguish long COVID.</AbstractText><AbstractText Label="CLINICAL TRIALS REGISTRATION">NCT04610515.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spatz</LastName><ForeName>Erica S</ForeName><Initials>ES</Initials><Identifier Source="ORCID">0000-0002-1557-7713</Identifier><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gottlieb</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wisk</LastName><ForeName>Lauren E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Los Angeles, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Policy and Management, Fielding School of Public Health at UCLA, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Jill</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Harborview Center for Prehospital Emergency Care, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Anna Marie</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gentile</LastName><ForeName>Nicole L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>Departments of Family Medicine and Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Mandy J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, UTHealth Houston, McGovern Medical School, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huebinger</LastName><ForeName>Ryan M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, UTHealth Houston, McGovern Medical School, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Idris</LastName><ForeName>Ahamed H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinsman</LastName><ForeName>Jeremiah</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koo</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shu-Xia</ForeName><Initials>SX</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plumb</LastName><ForeName>Ian D</ForeName><Initials>ID</Initials><AffiliationInfo><Affiliation>National Center for Immunizations and Respiratory Diseases, Centers for Disease Control &amp; Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saydah</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Center for Immunizations and Respiratory Diseases, Centers for Disease Control &amp; Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slovis</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stephens</LastName><ForeName>Kari A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Departments of Family Medicine, Harborview Center for Prehospital Emergency Care, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unger</LastName><ForeName>Elizabeth R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ralph C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Huihui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hota</LastName><ForeName>Bala</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Chief Informatics Officer, Tendo Systems, Inc., San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elmore</LastName><ForeName>Joann G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Los Angeles, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Policy and Management, Fielding School of Public Health at UCLA, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinstein</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Rush University Medical Center and Cook County Health, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkatesh</LastName><ForeName>Arjun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04610515</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>75D30120C08008</GrantID><Acronym>IP</Acronym><Agency>NCIRD CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>75D30120C08008</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060145" MajorTopicYN="Y">Text Messaging</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">outcomes</Keyword><Keyword MajorTopicYN="N">registry</Keyword></KeywordList><CoiStatement>Potential conflicts of interest . All authors: No potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>27</Day><Hour>0</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36573005</ArticleId><ArticleId IdType="mid">NIHMS2008302</ArticleId><ArticleId IdType="pmc">PMC11361781</ArticleId><ArticleId IdType="doi">10.1093/cid/ciac966</ArticleId><ArticleId IdType="pii">6961096</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Post-COVID Conditions. Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html.
Accessed February 23, 2022.</Citation></Reference><Reference><Citation>Arjun MC, Singh AK, Pal D, et al. Prevalence, characteristics, and predictors of Long COVID among diagnosed cases of COVID-19. medRxiv. 2022:2022.01.04.21268536. doi:10.1101/2022.01.04.21268536</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.04.21268536</ArticleId><ArticleId IdType="pmc">PMC9767341</ArticleId><ArticleId IdType="pubmed">36538532</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue JK, Franko NM, McCulloch DJ, et al. Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw Open. Feb 1 2021;4(2):e210830. doi:10.1001/jamanetworkopen.2021.0830</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0830</ArticleId><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Havervall S, Rosell A, Phillipson M, et al. Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. JAMA. May 18 2021;325(19):2015&#x2013;2016. doi:10.1001/jama.2021.5612</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.5612</ArticleId><ArticleId IdType="pmc">PMC8027932</ArticleId><ArticleId IdType="pubmed">33825846</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med Apr 2021;27(4):601&#x2013;615. doi:10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M, Elliott J, Chadeau-Hyam M, et al. Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people. medRxiv. 2021:2021.06.28.21259452. doi:10.1101/2021.06.28.21259452</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.28.21259452</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. Aug 2021;38:101019. doi:10.1016/j.eclinm.2021.101019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert N, Corps S, El-Azab S, et al. COVID-19 Survivors' Reports of the Timing, Duration, and Health Impacts of Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection. 2021:</Citation></Reference><Reference><Citation>Wisk LE, Nichol G, Elmore JG. Toward Unbiased Evaluation of Postacute Sequelae of SARS-CoV-2 Infection: Challenges and Solutions for the Long Haul Ahead. Ann Intern Med Mar 8 2022;doi:10.7326/M21-4664</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-4664</ArticleId><ArticleId IdType="pmc">PMC8906529</ArticleId><ArticleId IdType="pubmed">35254883</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med May 2022;28(5):911&#x2013;923. doi:10.1038/s41591-022-01810-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01810-6</ArticleId><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Laughlin KN, Thompson M, Hota B, et al. Study protocol for the Innovative Support for Patients with SARS-COV-2 Infections Registry (INSPIRE): a longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection. medRxiv. 2022:2021.08.01.21261397. doi:10.1101/2021.08.01.21261397</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.08.01.21261397</ArticleId><ArticleId IdType="pmc">PMC8893622</ArticleId><ArticleId IdType="pubmed">35239680</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x13d;aughlin KN, Thompson M, Hota B, et al. Study protocol for the Innovative Support for Patients with SARS-COV-2 Infections Registry (INSPIRE): A longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection. PLoS One. 2022;17(3):e0264260. doi:10.1371/journal.pone.0264260</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0264260</ArticleId><ArticleId IdType="pmc">PMC8893622</ArticleId><ArticleId IdType="pubmed">35239680</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandler CX, Wyller VBB, Moss-Morris R, et al. Long COVID and Post-infective Fatigue Syndrome: A Review. Open Forum Infect Dis 2021;8(10):ofab440&#x2013;ofab440. doi:10.1093/ofid/ofab440</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab440</ArticleId><ArticleId IdType="pmc">PMC8496765</ArticleId><ArticleId IdType="pubmed">34631916</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner D, Nisenbaum R, Heim C, Jones JF, Unger ER, Reeves WC. Psychometric properties of the CDC Symptom Inventory for assessment of Chronic Fatigue Syndrome. Population Health Metrics. 2005/07/22 2005;3(1):8. doi:10.1186/1478-7954-3-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1478-7954-3-8</ArticleId><ArticleId IdType="pmc">PMC1183246</ArticleId><ArticleId IdType="pubmed">16042777</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghali A, Lacout C, Ghali M, et al. Warning Signals of Post-Exertional Malaise in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Retrospective Analysis of 197 Patients. J Clin Med 2021;10(11):2517. doi:10.3390/jcm10112517</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10112517</ArticleId><ArticleId IdType="pmc">PMC8201170</ArticleId><ArticleId IdType="pubmed">34200126</ArticleId></ArticleIdList></Reference><Reference><Citation>Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol Oct 1989;46(10):1121&#x2013;3. doi:10.1001/archneur.1989.00520460115022</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1989.00520460115022</ArticleId><ArticleId IdType="pubmed">2803071</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner D, Nisenbaum R, Heim C, Jones JF, Unger ER, Reeves WC. Psychometric properties of the CDC Symptom Inventory for assessment of chronic fatigue syndrome. Popul Health Metr 2005;3:8&#x2013;8. doi:10.1186/1478-7954-3-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1478-7954-3-8</ArticleId><ArticleId IdType="pmc">PMC1183246</ArticleId><ArticleId IdType="pubmed">16042777</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoring Algorithm of CDC Symptom Inventory. https://www.cdc.gov/me-cfs/pdfs/wichita-data-access/si-scoring-algorithm.pdf.
Accessed February 18, 2022.</Citation></Reference><Reference><Citation>Reeves WC, Wagner D, Nisenbaum R, et al. Chronic fatigue syndrome--a clinically empirical approach to its definition and study. BMC Med Dec 15 2005;3:19. doi:10.1186/1741-7015-3-19</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-3-19</ArticleId><ArticleId IdType="pmc">PMC1334212</ArticleId><ArticleId IdType="pubmed">16356178</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda M, Nordstr&#xf6;m R, Matsubayashi T. Suicide and mental health during the COVID-19 pandemic in Japan. J Public Health (Oxf). 2021:fdab113. doi:10.1093/pubmed/fdab113</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pubmed/fdab113</ArticleId><ArticleId IdType="pmc">PMC8083330</ArticleId><ArticleId IdType="pubmed">33855451</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong ASF, Pearson RM, Adams MJ, et al. Mental health before and during the COVID-19 pandemic in two longitudinal UK population cohorts. Br J Psychiatry. 2021;218(6):334&#x2013;343. doi:10.1192/bjp.2020.242</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.2020.242</ArticleId><ArticleId IdType="pmc">PMC7844173</ArticleId><ArticleId IdType="pubmed">33228822</ArticleId></ArticleIdList></Reference><Reference><Citation>Ping W, Zheng J, Niu X, et al. Evaluation of health-related quality of life using EQ-5D in China during the COVID-19 pandemic. PLoS One. 2020;15(6):e0234850. doi:10.1371/journal.pone.0234850</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0234850</ArticleId><ArticleId IdType="pmc">PMC7302485</ArticleId><ArticleId IdType="pubmed">32555642</ArticleId></ArticleIdList></Reference><Reference><Citation>Sneller MC, Liang CJ, Marques AR, et al. A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings. Ann Intern Med May 24 2022;doi:10.7326/M21-4905</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-4905</ArticleId><ArticleId IdType="pmc">PMC9128805</ArticleId><ArticleId IdType="pubmed">35605238</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull-Otterson L, Baca S, Saydah S, et al. Post&#x2013;COVID Conditions Among Adult COVID-19 Survivors Aged 18&#x2013;64 and &#x2265;65 Years &#x2014; United States, March 2020&#x2013;November 2021. MMWR Morb Mortal Wkly Rep ePub: 24 May 2022. DOI: 10.15585/mmwr.mm7121e1external icon.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7121e1external</ArticleId></ArticleIdList></Reference><Reference><Citation>Pray IW, Ford L, Cole D, et al. Performance of an Antigen-Based Test for Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University Campuses &#x2014; Wisconsin, September&#x2013;October 2020. MMWR Morb Mortal Wkly Rep 2021;69:1642&#x2013;1647. DOI: 10.15585/mmwr.mm695152a3external.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm695152a3external</ArticleId><ArticleId IdType="pmc">PMC9191905</ArticleId><ArticleId IdType="pubmed">33382679</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>